1. Scrip
  2. >>New Products

3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

Home-Grown Partnership Pays Dividends

 
• By Brian Yang

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

winners from China NRDL scheme
FIRST SUBCUTANEOUS IMMUNO-ONCOLOGY DRUG APPROVAL FROM CHINA'S 3D MED AND ALPHAMAB • Source: Alamy

On 25 November, China's National Medical Products Administration granted a green light to envafolimab (KN035), the first humanized anti-PD-L1 single domain and human IgG1 Fc antibody formulated for subcutaneous injection, developed by 3D Medicines Corp. and Alphamab Oncology.

3D Med chief medical officer David Liu touted it as a “landmark approval representing the first approval of a subcutaneously administered PD(L)1 antibody by a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Scrip

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.